Lacidofil®

posted on: Wednesday May 4, 2011

Proprietary Probiotic Blend Containing a Minimum of Two Billion LiveOrganisms Per Capsule

XYMOGEN has partnered with world-renowned probiotic laboratory Institut Rosell in bringing Rosell’sleading strain-specifi c pharmaceutical probiotic formulas, including Lacidofil®, to the U.S. professionalnutraceutical market. Human clinical trials on hundreds of patients utilizing Lacidofi l have demonstratedbenefi cial probiotic effects. Laboratory analysis has demonstrated Lacidofi l possesses a much higher PI(Proliferation Index) than other strains tested. The degree to which bacteria adhere to and proliferate inthe bowel is a most important consideration in assessing probiotic effi cacy.